# Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma

> **NCT02267083** · PHASE2 · COMPLETED · sponsor: **Gem Pharmaceuticals** · enrollment: 22 (actual)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **DRUG:** GPX-150 for Injection

## Key facts

- **NCT ID:** NCT02267083
- **Lead sponsor:** Gem Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-07
- **Primary completion:** 2015-11-11
- **Final completion:** 2016-08-18
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2018-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02267083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02267083, "Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma". Retrieved via MORVS 2026-10-15 from https://api.morvs.ai/clinical/NCT02267083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*